KRN5500: A novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis

John G. Byrd, David M. Lucas, Andrew P. Mone, Joshua B. Kitner, Joseph J. Drabick, Michael R. Grever

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Fingerprint Dive into the research topics of 'KRN5500: A novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds